- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
December 10th, 2007
Arch Venture Partners, the 21-year-old venture capital firm whose Seattle area investments include Allozyne, Trubion Pharmaceuticals and VLST, has raised a $400 million venture fund.
It is the firm's seventh fund. The money will be invested in early-stage companies in the biotechnology, advanced materials, nanotechnology and semiconductor sectors.
|Related News Press|
Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016
ANU invention to inspire new night-vision specs December 7th, 2016
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Journal Nanotechnology Progress International (JONPI), newest edition out December 7th, 2016